arbiter
JournalsAccount

Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany

Marie Engelhard et al.

European Journal of Health Economics2026https://doi.org/10.1007/s10198-025-01890-4article
AJG 2ABDC A
Weight
0.50

Abstract

Our study demonstrated higher anti-CMV drug acquisition costs and overall direct treatment costs in patients receiving letermovir prophylaxis compared to controls. However, these higher costs are accompanied by significantly improved clinical outcomes.

Open via your library →

Cite this paper

https://doi.org/https://doi.org/10.1007/s10198-025-01890-4

Or copy a formatted citation

@article{marie2026,
  title        = {{Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany}},
  author       = {Marie Engelhard et al.},
  journal      = {European Journal of Health Economics},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1007/s10198-025-01890-4},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.